Your browser doesn't support javascript.
loading
Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial.
Gueyffier, F; Subtil, F; Bejan-Angoulvant, T; Zerbib, Y; Baguet, J P; Boivin, J M; Mercier, A; Leftheriotis, G; Gagnol, J P; Fauvel, J P; Giraud, C; Bricca, G; Maucort-Boulch, D; Erpeldinger, S.
Afiliação
  • Gueyffier F; 1] Centre d'Investigations Cliniques CIC201 Inserm and Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France [2] UMR 5558, CNRS, Villeurbanne, France [3] Université Claude Bernard Lyon1, Lyon, France.
  • Subtil F; 1] UMR 5558, CNRS, Villeurbanne, France [2] Université Claude Bernard Lyon1, Lyon, France [3] Service de Biostatistique, Hospices Civils de Lyon, Lyon, France.
  • Bejan-Angoulvant T; Service de Pharmacologie Clinique, Centre Hospitalier Régional et Universitaire de Tours, UMR 7292, CNRS, Université François Rabelais, Tours, France.
  • Zerbib Y; 1] Université Claude Bernard Lyon1, Lyon, France [2] Department of General Practice, Université Claude Bernard Lyon1, Lyon, France [3] Sciences et Société; Historicité, Éduction et Pratiques (S2HEP), Villeurbanne, France.
  • Baguet JP; 1] Department of Cardiology, Centre Hospitalier Universitaire, Grenoble, France [2] INSERM 1039, Bioclinic Radiopharmaceutics Laboratory, Université Joseph Fourier, Grenoble, France.
  • Boivin JM; Centre d'Investigations Cliniques Plurithématique, CIC-P-Inserm CHU de Nancy, Institut Lorrain du cœur et des vaisseaux Louis Mathieu, Université Henri Poincaré Nancy, 4 allée du Morvan, Vandœuvre lès Nancy, France.
  • Mercier A; 1] Department of General Practice, Faculté de Médecine, Rouen University, Rouen, France [2] CIC Inserm 0204 CHU de Rouen, Rouen, France.
  • Leftheriotis G; Laboratoire d'Explorations Fonctionnelles Vasculaires, CHU Angers, Angers, France.
  • Gagnol JP; Cardiology department, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.
  • Fauvel JP; Department of Nephrology and Hypertension, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
  • Giraud C; 1] Centre d'Investigations Cliniques CIC201 Inserm and Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France [2] UMR 5558, CNRS, Villeurbanne, France [3] Université Claude Bernard Lyon1, Lyon, France.
  • Bricca G; Exploration Fonctionnelle Endocrinienne et Métabolique, Centre de Biologie Nord, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
  • Maucort-Boulch D; 1] Université Claude Bernard Lyon1, Lyon, France [2] Service de Biostatistique, Hospices Civils de Lyon, Lyon, France.
  • Erpeldinger S; Department of General Practice, Université Claude Bernard Lyon1, Lyon, France.
J Hum Hypertens ; 29(1): 22-7, 2015 Jan.
Article em En | MEDLINE | ID: mdl-24739801
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Perindopril / Diuréticos / Pressão Arterial / Hipertensão / Indapamida / Anti-Hipertensivos Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Enzima Conversora de Angiotensina / Perindopril / Diuréticos / Pressão Arterial / Hipertensão / Indapamida / Anti-Hipertensivos Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2015 Tipo de documento: Article